Emergence of precision medicine has shaped the way we diagnose and manage patients
with prostate cancer. The use of novel genomic biomarkers alongside existing clinical
risk classifiers such as NCCN based categories has improved prostate cancer risk stratification
and outcome prediction. However, lack of racial diversity in the studies that developed
these prognostic biomarkers limits clinical utility of existing biomarkers across
subpopulation. This study clearly shows that self-identified Black men classified
as being low risk with standard NCCN based risk criteria may harbor genomically aggressive
disease. Considering that current recommendations for active surveillance are based
on NCCN risk criteria, it is vital to understand the genomic risk of prostate cancer
within the subset of patients eligible for active surveillance who are more likely
to experience adverse outcomes due to their underlying genomic risk.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.
